Patients initiating specialty medication therapy for complex rare disease face many challenges, including complex regimens and treatment tolerability considerations that can lead to early therapy discontinuation. Despite appropriate patient onboarding, disease state education, and treatment education, VytlOne Specialty identified that there was often an adherence gap after the first month of therapy. Read More >